These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 32828964)

  • 1. Role of induced pluripotent stem cells in lysosomal storage diseases.
    Kido J; Nakamura K; Era T
    Mol Cell Neurosci; 2020 Oct; 108():103540. PubMed ID: 32828964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delineating the Neuropathology of Lysosomal Storage Diseases Using Patient-Derived Induced Pluripotent Stem Cells.
    Sabitha KR; Chandran D; Shetty AK; Upadhya D
    Stem Cells Dev; 2022 May; 31(9-10):221-238. PubMed ID: 35316126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induced pluripotent stem cell technology for disease modeling and drug screening with emphasis on lysosomal storage diseases.
    Huang HP; Chuang CY; Kuo HC
    Stem Cell Res Ther; 2012 Aug; 3(4):34. PubMed ID: 22925465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stem Cell Applications in Lysosomal Storage Disorders: Progress and Ongoing Challenges.
    Köse S; Aerts-Kaya F; Uçkan Çetinkaya D; Korkusuz P
    Adv Exp Med Biol; 2021; 1347():135-162. PubMed ID: 33977438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysosomal storage diseases: current therapies and future alternatives.
    Leal AF; Espejo-Mojica AJ; Sánchez OF; Ramírez CM; Reyes LH; Cruz JC; Alméciga-Díaz CJ
    J Mol Med (Berl); 2020 Jul; 98(7):931-946. PubMed ID: 32529345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene therapy for lysosomal storage diseases: progress, challenges and future prospects.
    Seregin SS; Amalfitano A
    Curr Pharm Des; 2011; 17(24):2558-74. PubMed ID: 21774776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease models for the development of therapies for lysosomal storage diseases.
    Xu M; Motabar O; Ferrer M; Marugan JJ; Zheng W; Ottinger EA
    Ann N Y Acad Sci; 2016 May; 1371(1):15-29. PubMed ID: 27144735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysosomal storage disorders: old diseases, present and future challenges.
    Klein AD; Futerman AH
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():59-63. PubMed ID: 24380123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SnapShot: Lysosomal Storage Diseases.
    Martina JA; Raben N; Puertollano R
    Cell; 2020 Feb; 180(3):602-602.e1. PubMed ID: 32032518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SNX8 enables lysosome reformation and reverses lysosomal storage disorder.
    Li X; Xiang C; Zhu S; Guo J; Liu C; Wang A; Cao J; Lu Y; Neculai D; Xu P; Feng XH
    Nat Commun; 2024 Mar; 15(1):2553. PubMed ID: 38519472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New strategies for the treatment of lysosomal storage diseases (review).
    Parenti G; Pignata C; Vajro P; Salerno M
    Int J Mol Med; 2013 Jan; 31(1):11-20. PubMed ID: 23165354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mass spectrometry-based proteomics in neurodegenerative lysosomal storage disorders.
    Li W; Cologna SM
    Mol Omics; 2022 May; 18(4):256-278. PubMed ID: 35343995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induced pluripotent stem cell models of lysosomal storage disorders.
    Borger DK; McMahon B; Roshan Lal T; Serra-Vinardell J; Aflaki E; Sidransky E
    Dis Model Mech; 2017 Jun; 10(6):691-704. PubMed ID: 28592657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New tools can propel research in lysosomal storage diseases.
    Hertz E; Glasstetter LM; Chen Y; Sidransky E
    Mol Genet Metab; 2023 Dec; 140(4):107729. PubMed ID: 37951057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling neuronopathic storage diseases with patient-derived culture systems.
    Zunke F; Mazzulli JR
    Neurobiol Dis; 2019 Jul; 127():147-162. PubMed ID: 30790616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications.
    Biffi A
    Mol Ther; 2017 May; 25(5):1155-1162. PubMed ID: 28389320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in therapies for neurological lysosomal storage disorders.
    Ellison S; Parker H; Bigger B
    J Inherit Metab Dis; 2023 Sep; 46(5):874-905. PubMed ID: 37078180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant autophagy in lysosomal storage disorders marked by a lysosomal SNARE protein shortage due to suppression of endocytosis.
    Tanaka H; Tsuji D; Watanabe R; Ohnishi Y; Kitaguchi S; Nakae R; Teramoto H; Tsukimoto J; Horii Y; Itoh K
    J Inherit Metab Dis; 2022 Nov; 45(6):1191-1202. PubMed ID: 36102069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Human Induced Pluripotent Stem Cells and Kidney Organoids To Develop a Cysteamine/mTOR Inhibition Combination Therapy for Cystinosis.
    Hollywood JA; Przepiorski A; D'Souza RF; Sreebhavan S; Wolvetang EJ; Harrison PT; Davidson AJ; Holm TM
    J Am Soc Nephrol; 2020 May; 31(5):962-982. PubMed ID: 32198276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving therapies in neuronopathic LSDs: opportunities and challenges.
    Rajan DS; Escolar ML
    Metab Brain Dis; 2022 Oct; 37(7):2245-2256. PubMed ID: 35442005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.